Olivia Meredith
Investor·Norwest
Bio
Professional summary
Olivia Meredith is a growth equity investor at Norwest focused on investments across technology, business services, media, and consumer sectors. Before joining Norwest, she worked at Congress Asset Management in Boston and at Goldman Sachs in New York. She graduated from Northeastern University with a bachelor's degree in business administration and finance.
Background
Career, education, and skills
Career history
- NorwestInvestor
- Congress Asset ManagementInvestment Professional
- Goldman SachsInvestment Professional
Education
- Northeastern UniversityBachelor's in Business Administration and Finance
Other partners at Norwest
12 more profiles
Abishek Balakrishnan
Investor
Norwest
Norwest growth equity investor focused on healthcare services, IT, devices, and digital health.
Aidan Greenstein
Investor
Norwest
Norwest growth equity investor covering technology, business services, media, and consumer.
Amalia Mackenzie
Investor
Norwest
Norwest venture investor focused on consumer and enterprise software.
Amy Brand
Investor
Norwest
Norwest growth equity investor and former Barclays financial sponsors banker.
Andrew Ellis
Investor
Norwest
Norwest growth equity investor focused on software and tech-enabled services.
Angela Johnson
Vice President
Norwest
Norwest growth equity VP focused on technology, business services, media, and consumer.
Anjini K.
Investor
Norwest
Norwest healthtech venture investor with prior Oscar Health and McKinsey experience.
Ankit Prasad
Norwest India
Norwest
Norwest India investor focused on venture and growth equity across Indian companies.
Apurva Oak
Investor
Norwest
Healthcare growth investor focused on software and services at Norwest.
Aria Shah
Investment Professional
Norwest
Growth investment professional with healthcare and venture capital experience.
Assaf Harel
Partner
Norwest
Norwest Partner focused on Israeli-related multi-stage technology investments.
Brian Matesic, MD
Principal
Norwest
Life sciences investor backing early- to mid-stage biotech and medtech companies.